8-K: Accuray Withdraws FY26 Guidance Amid Geopolitical Uncertainty

Accuray Incorporated reported a 7% decrease in third-quarter fiscal 2026 revenue to $104.8 million and withdrew its full-year financial guidance due to geopolitical instability impacting shipments in the Middle East.

Summary

• Accuray Incorporated announced financial results for the third quarter ended March 31, 2026, reporting total net revenue of $104.8 million, a 7% decrease year-over-year.
• Product revenue decreased by 13% to $49.7 million, while service revenue saw a slight decrease of 1% to $55.1 million.
• Total gross profit was $25.3 million, with a gross margin of 24.1%, down from 27.9% in the prior year, attributed to higher parts consumption and logistics costs.
• Operating expenses increased by 12% to $34.4 million, including $6.5 million in restructuring charges. Excluding these charges, operating expenses decreased by 9% year-over-year.
• The company reported a net loss of $11.8 million, or $0.09 per share, compared to a net loss of $1.3 million, or $0.01 per share, in the prior year.
• Adjusted EBITDA was $3.8 million, down from $6.0 million in the prior fiscal year's third quarter.
• Gross product orders were $48.5 million, a decrease from $71.2 million in the prior year, resulting in a book-to-bill ratio of 1.0.
• Order backlog stood at $356.2 million as of March 31, 2026, a 21% decrease from the prior fiscal year's third quarter.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the significant revenue decline, widening net loss, and withdrawal of financial guidance, despite some positive progress on the transformation plan.

Positives

• The transformation plan is delivering ahead of expectations, achieving approximately $10 million in cost and margin improvements through the fiscal third quarter, exceeding the $12 million FY26 target.
• Commercial leadership has been strengthened with the appointment of Paul Miele as Chief Commercial Officer.
• Strategic partnerships are gaining momentum, expanding Accuray's ecosystem.
• The company will showcase customer-driven product enhancements at the upcoming European Society for Radiotherapy and Oncology (ESTRO) Congress.

Negatives

• Total net revenue decreased by 7% to $104.8 million in Q3 FY26 compared to $113.2 million in Q3 FY25.
• Product revenue decreased by 13% to $49.7 million in Q3 FY26 compared to $57.3 million in Q3 FY25.
• Gross profit margin decreased to 24.1% from 27.9% in the prior year's quarter.
• Operating expenses increased by 12% to $34.4 million, including $6.5 million in restructuring charges.
• Net loss widened to $11.8 million ($0.09 per share) in Q3 FY26 from $1.3 million ($0.01 per share) in Q3 FY25.
• Adjusted EBITDA decreased to $3.8 million in Q3 FY26 from $6.0 million in Q3 FY25.
• Gross product orders decreased by 32% to $48.5 million in Q3 FY26 compared to $71.2 million in Q3 FY25.
• Order backlog decreased by 21% to $356.2 million as of March 31, 2026, compared to the prior fiscal year's third quarter.

Risks

• Geopolitical uncertainty in the Middle East is materially impacting product shipments and service revenue, with installations delayed in several markets within the region.
• The company withdraws its financial guidance for fiscal year 2026 due to these geopolitical uncertainties.
• Higher net parts consumption of $3.2 million and higher than average logistics and duties costs contributed to the decrease in gross margin rate.
• Global macroeconomic conditions, international tariffs, and supply chain challenges are noted as potential impacts.
• Risks associated with international operations, foreign currency fluctuations, and potential changes in tariffs, export controls, and trade sanctions are present.
• The company has substantial outstanding indebtedness and must maintain compliance with financial covenants.
• Delays in regulatory approvals or the development/release of new offerings could impact the business.
• Geopolitical uncertainty, including armed conflict or political instability, could affect system installations, service revenue, and transaction completion in affected markets.

Future Outlook

The company has withdrawn its financial guidance for fiscal year 2026, specifically for total net revenue and Adjusted EBITDA, due to geopolitical uncertainty in the Middle East impacting product shipments and installations. The outlook will be revisited when fiscal fourth quarter results are reported. The transformation plan is expected to deliver cost and margin improvements exceeding the $12 million FY26 target.

Management Comments

• "During the quarter, we made meaningful progress executing against the transformation plan we launched in December. We are already seeing tangible benefits from these initiatives, including approximately $10 million in realized margin improvements through the fiscal third quarter, positioning us ahead of our original expectations."
• "We have also strengthened our leadership team with experienced talent in key strategic areas and continue to enhance our technology platform through highly strategic partnerships focused on advancing real-time adaptation to patient and tumor motion during treatment, a core differentiator of Accuray's technology."
• "Taken together, we believe these actions will improve execution, strengthen profitability, and create meaningful long-term value for our shareholders."
• "Overall, we are encouraged by the progress we are making and remain confident in our strategy and our ability to execute on the areas within our control."
• "However, the current geopolitical environment has created significant unpredictability around the timing of installations in several key Middle Eastern markets. Given these uncertainties, we believe it is prudent to withdraw financial guidance at this time, specifically as it relates to total net revenue and Adjusted EBITDA, and revisit our outlook when we report fiscal fourth quarter results."

Industry Context

StockSavvy.ai notes that Accuray's withdrawal of guidance due to geopolitical instability in the Middle East highlights the vulnerability of global supply chains and installation schedules in the medical device sector, particularly for complex capital equipment like radiation oncology systems. Competitors may face similar challenges, but Accuray's specific mention of this region suggests a concentrated impact.

Management Changes

Stakeholder Impact

• Shareholders: The withdrawal of guidance and decreased financial performance may negatively impact shareholder confidence and stock price. However, progress on the transformation plan and strategic partnerships could offer long-term value.
• Employees: Restructuring charges and potential impacts from geopolitical uncertainty could affect employee morale and job security.
• Customers: Delays in installations in the Middle East may impact customer operations and satisfaction. The company's focus on product enhancements aims to reinforce clinical excellence and workflow efficiency.
• Suppliers: Geopolitical uncertainty and reduced product shipments could impact demand and payment cycles for suppliers.

Next Steps

• Accuray will host a conference call on May 6, 2026, to discuss Q3 FY26 results and corporate developments.
• The company will showcase product enhancements at the ESTRO Congress in Stockholm, Sweden (May 15-19, 2026).
• The company will revisit its fiscal 2026 outlook when reporting fourth-quarter results.

Key Dates

Recommendation

While the company is making progress on its transformation plan and strengthening leadership, the significant decline in revenue, widening net loss, and withdrawal of guidance due to geopolitical instability are concerning. The order backlog reduction also signals near-term challenges. A 'hold' recommendation is appropriate given the mixed signals, awaiting clearer visibility on the impact of geopolitical issues and the effectiveness of the transformation plan.

Keywords

Accuray, 8-K, Financial Results, Radiation Therapy, Oncology, Medical Devices, Revenue, Guidance Withdrawal